US FDA's final rule on post-market reporting requirements for combination products is likely to be a welcome addition for industry.
The final rule, published Dec. 20, clarifies its scope, aims to minimize duplicative reporting, clarifies the definitions of certain terms and includes additional reporting requirements to address specific safety concerns...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?